Synopsis
Interpret PSA in context, use pre-biopsy multiparametric MRI and risk-adapted biopsy, distinguish localised from metastatic disease and sequence surveillance, local treatment and systemic androgen-axis therapy while protecting bone and metabolic health.
- Asymptomatic PSA abnormality is a pivotal clue in Prostate cancer: Many localised cancers are detected after informed PSA testing rather than symptoms and require risk estimation rather than automatic treatment.
- Immediate priority in unstable Prostate cancer: Activate the MSCC pathway for spinal symptoms, catheterise and treat infection or renal obstruction when safe, involve urology urgently and do not delay emergency care while obtaining an elective PSA or biopsy.
- PSA with informed discussion is used early to estimate cancer probability while explaining false positives, overdiagnosis and consequences of further tests. Interpret against age, prostate volume, trend, examination, infection, ejaculation and instrumentation; repeat a moderately raised result under appropriate conditions when safe.
- Multiparametric MRI before biopsy refines the next decision because nICE recommends pre-biopsy mpMRI; Likert or PI-RADS suspicion guides targeted sampling, but a negative MRI does not eliminate clinically significant cancer in every risk context.
- Move from PSA to MRI and biopsy: Discuss PSA limitations, exclude or treat infection and repeat a moderately raised result when appropriate, using life expectancy and preferences in referral decisions.
- Match treatment burden to cancer risk: Compare radical prostatectomy and external-beam or brachytherapy options using urinary, bowel, sexual, anaesthetic and oncological outcomes.
- A major avoidable harm is metastatic spinal cord compression; Vertebral or epidural disease can cause irreversible weakness and sphincter loss unless dexamethasone, MRI and definitive treatment occur urgently.
- A common diagnostic trap is benign prostatic enlargement: Common transition-zone enlargement causes urinary symptoms and PSA elevation without the grade and invasion pattern of cancer.
Key red flags
New back pain, leg weakness, sensory change or sphincter dysfunction suggests metastatic spinal cord compression.
Acute urinary retention, anuria, hydronephrosis or rising creatinine suggests clinically important outlet or ureteric obstruction.
Bone pain, pathological fracture, weight loss or anaemia suggests metastatic burden.
Visible haematuria or recurrent infection needs independent bladder and urinary-tract assessment rather than attribution to prostate cancer.
A rapidly rising or persistently abnormal PSA remains concerning after infection, instrumentation and benign causes are considered.
Weakness, gait change, sensory level or bladder dysfunction with back pain is suspected MSCC and requires emergency imaging.
Investigation priorities
Estimate cancer probability while explaining false positives, overdiagnosis and consequences of further tests.
Management branches
PSA, examination, symptoms or incidental imaging creates a clinically meaningful possibility of prostate cancer.
- Discuss PSA limitations, exclude or treat infection and repeat a moderately raised result when appropriate, using life expectancy and preferences in referral decisions.
- Obtain pre-biopsy multiparametric MRI and review PSA density, lesion score, examination and family or inherited risk.
- Use targeted plus protocolled systematic transperineal biopsy when risk remains sufficient, reporting ISUP grade, core burden and histological variants.